Monday, December 23, 2013

What is Cystinuria?


What is Cystinuria?

Cystinuria is an autosomal-recessive disorder that alters how the kidneys reabsorbs with amino acids. The resultant improper reabsorption causes a loss of large amounts of amino acids into the urine, allowing the urine to become concentrated with amino acids. Cystine, in large concentrations, start to form the crystals that clump to form the kidney stones, a prominent characteristic of Cystinuria. As one of the most common genetic disorders in amino acid transport, approximately 1 in 10,000 people are affected by cystinuria with most of those symptomatic for the kidney stones being under the age of 40.

Genetics

Being autosomal recessive, the faulty gene that causes cystinuria is always inherited from both parents, which implies that both the parents must be carrying the faulty gene. Due to it being recessive, the parents could appear either as symptomatic for cystinuria or asymptomatic carriers. Likewise, affected individuals will pass down the faulty gene to their children.

Symptoms and diagnostic tests

Cystinurics would often experience symptoms such as:
  • Hematuria (a.k.a. Bloody urine)
  • Nausea
  • Vomiting
  • Chronic pain
  • Pain in abdomen/back
Serious complications like kidney infection, uretal obstruction or even kidney failure can occur if cystinuria is left untreated. Tests such as an abdominal CT scan, MRI, Intravenous pyelogram (IVP) or a 24-hour urine collection can be done to detect kidney stones for early treatment.

Biochemistry behind Cystinuria

Cystinuria is caused by the mutations in the SLC3A1 and SLC7A9 genes. The SLC3A1 and SLC7A9 genes code for two different subunits that associate with each other to form the active transporter for cystine. The mutation then causes the disruption of the transporter protein from reabsorbing the amino acid from the filtered fluid in the proximal renal tubules of the kidneys. Cystine in large concentrations then forms crystals which clump to form the kidney stones.

Cures/Prevention

While there are no direct ways of curing cystinuria due to its genetic origin, there is still treatment to prevent the formation of kidney stones as much possible in a variety of ways.

Hydration is one of the oldest and most effective way to prevent cystine crystal formation. This works as it tries to dilute the urine as much as possible to lower the overall concentrations of cystine in the urine which directly prevents the formation of the cystine crystal. Suggested intake volumes are around 4 to about 4.5 litres of alkalizing beverages that are rich in bicarbonate and low in sodium like mineral water or citric juices. Lowering sodium intake of the patient's diet also has a similar effect.

Alkalinization of the urine can also help prevent the precipitation of the cystine crystals and can also help dissolve existing cystine crystals due to the fact that the solubility of cystine crystals greatly increases at higher pH levels. A typical way of doing this is by prescribing Potassium citrate to the patient at a dose that would maintain a urine pH of about 7.5. However, constant monitoring of urinary pH is required with any form of alkalinization therapy.

Chelating agents such as Penicillamine or Alpha-mercaptopropionylglycine are able to dissociate the cystine molecules into products that are more soluble, preventing formation of crystals and dissolving crystals to a certain extent. Despite its effectiveness, the chelating agents are used only if alkalinization and hydration fails due to the adverse side effects like gastrointestinal intolerance, arthralgia or rash that can occur due to intake of the chelating agents.


If renal stones that are too large to be dissolved feasibly are detected via the various diagnostic tests, a non-invasive procedure known as an extracorporeal shock wave lithotripsy (ESWL) can be performed. This technique uses focused, high-intensity acoustic pulses to crush stones up to 1.5 cm in diameter in the kidney into smaller fragments that can then be passed out through the urine, preventing further obstruction.

However due to uncontrolled growth, some stones are able to grow to the point at which they are unlikely to dissolve or break and pose a more serious risk. In this case, its is normally suggested to remove the kidney stones from the patient through invasive surgery.

Percutaneous nephrolithotomy (PCNL) is the standard invasive surgical procedure for the removal of cystine calculi that are larger than 1 cm in diameter. This procedure is normally used upon failure of fragmenting the stones via ESWL due to the fact that complications may arise by doing this procedure such as, injury to the colon, renal blood vessels or sepsis. If even percutaneous nephrolithotomy fails, open surgery to remove the stones via laser or electrohydraulic lithotripsy can be done.

12 comments:

  1. With regards to:
    "The mutation then causes the disruption of the transporter protein from reabsorbing the amino acid from the filtered fluid in the proximal renal tubules of the kidneys."
    How actually is the mechanism of the disruption of the transporter protein? Does the mutation activate chemicals such as release factors that catalyse the release of transporter proteins from the amino acids, or do these mutations induce changes/release more chemicals that instead bind to these amino acids (i.e. similar to a inhibitor binding mechanism) and block off the transporter protein from binding (or reabsorbing?) the amino acids?

    Also, am I right to assume that Nephrolithotripsy is a smaller scale surgical procedure used to remove the kidney stones than the open surgery? I mean, do we consider both as open surgery due to the invasive nature of both surgical procedures?

    Thanks. ;)

    ReplyDelete
    Replies
    1. Hi Kang Ming!
      The mutation in the SLC3A1 and SLC7A9 genes actually do not release any proteins or factors that inhibit the binding/transport of the amino acid by the transporter protein. The mutation simply results in a deformed transporter protein which loses its 3D configuration at its active binding sites, hence losing the ability to bind to the amino acid.

      Yes, you are right in that Nephrolithotripsy is considered a smaller scale surgical procedure as compared to open surgery. Nephrolithotripsy is actually a type of laparoscopic surgery, or better known as a keyhole surgery, which main goal is to minimize the invasiveness of the surgery for several advantages. The incision needed for a Nephrolithotripsy is typically only 0.5-1.5 cm! Open surgeries are classified by the large incisions, in which the surgeon has open access to the organs and tissues. Hence, Nephrolithotripsy is not considered to be an open surgery.

      Thanks for commenting! (:
      -Gabriel Ong

      Delete
    2. Thanks Gabriel! That was very informative and it cleared up a lot of doubts of mine.

      -kangming

      Delete
  2. Hi Kenneth and Gabriel! ^^

    Since cysteine and cystine are lost in great amounts, are there any significant consequences of cysteine deficiency?

    Thankewww :) Very informative blog :)

    ReplyDelete
    Replies
    1. Hi Wei Lu!

      Cysteine and Cystine are lost only at the nephron where the reabsorption is impaired. Both are still absorbed sufficiently in the intestine and used in the body before being "filtered out" at the nephron. There has been no statistical significance found between cystinuria and cysteine defiency.

      Thanks for commenting! (:
      -Gabriel Ong

      Delete
  3. Hi Gabriel and Kenneth! :D

    When you mention that parents who are carriers for this disease are symptomatic carriers, does this mean that they will have a milder form of this disease or otherwise?
    Thank you!:)

    ReplyDelete
  4. Hey Danesha good question! :D

    For cystinuria, if a parent is a symptomatic carrier, he/she will carry one of the recessive gene for cystinuria, And for the cystinuria effects on these carriers, they are divided into 3 subtypes; Type I, Type II, Type III. Type I will be for an unaffected individual, while type II and III will display milder form of the disease.

    Type I heterozygotes show normal aminoaciduria (normal AA levels in urine)
    Type II and III will show increased amino acid levels in urine, in particular certain amino acids (eg: cystine and lysine). However the possibility of them developing cystine stones is relatively lower than those homozygous recessive, affected individuals.

    Source: http://emedicine.medscape.com/article/435678-overview#a0104

    ReplyDelete
  5. Do patients with cystinuria have to rely on hydration/chelating agents/alkalinization for the rest of their lives?

    ReplyDelete
  6. HEY SHERMAN :D
    For patients with cystinuria, the duration which they undergo hydration alkalinization (generally known as standard treatment) depends on the effectiveness of these method, and it will not be a long term treatment. When these methods are not effective in reducing cystinuria, use of thiol drugs (chelating agents), such as D-penicillamine, alpha-MPG, and captopril, which dissolve cystine calculi over a long period of time. The chelating agents are often used for stone prevention after surgical debulking of the stone burden, and they possibly help soften cystine stones in preparation for ESWL.

    Source: http://emedicine.medscape.com/article/435678-treatment

    ReplyDelete